银屑病伴瘙痒的临床特点、发病机制及治疗研究进展

doi:10.35541/cjd.20190683

Abstract

Abstract: 【Abstract】 In the past, psoriasis was considered as a non-pruritic skin disease. In recent years, it has been gradually realized that pruritus is one of the factors that aggravate the disease burden of patients with psoriasis. This review mainly elaborates epidemiologic and clinical characteristics of pruritus in psoriasis, focuses on the role of abnormal expression of neuropeptides and abnormal distribution of nerve endings in neurogenic inflammation in the pathogenesis of pruritus, and introduces the effect of treatment of psoriasis on the relief of pruritus.

Key words: Psoriasis, Pruritus, Neurogenic inflammation, Neuropeptides

Guo Zhiwei, Jin Hongzhong. Pruritus in psoriasis: clinical characteristics, pathogenesis and treatment[J]. Chinese Journal of Dermatology, 2020, 53(12): 1029-1032.doi:10.35541/cjd.20190683

References ［43］

［1］	Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 national psoriasis foundation patient⁃membership survey［J］. Arch Dermatol, 2001,137（3）:280⁃284.
［2］	Damiani G, Cazzaniga S, Conic RR, et al. Pruritus characteristics in a large Italian cohort of psoriatic patients［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:1316⁃1324. doi: 10.1111/jdv. 15539.
［3］	O′Neill JL, Chan YH, Rapp SR, et al. Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web⁃based questionnaire［J］. Acta Derm Venereol, 2011,91（5）:537⁃540. doi: 10.2340/00015555⁃1126.
［4］	Gisondi P, Girolomoni G. Patients′ perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis （MAPP） survey［J］. J Dermatolog Treat, 2017,28（5）:390⁃393. doi: 10.1080/09546634. 2016.1255308.
［5］	Golbari NM, Porter ML, Kimball AB. Discordance between patient reported motivations to seek treatment for psoriasis compared to television advertisements［J］. J Drugs Dermatol, 2018,17（8）:886⁃887.
［6］	Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care［J］. Dermatol Ther （Heidelb）, 2019,9（1）:5⁃18. doi: 10.1007/s13555⁃018⁃0279⁃5.
［7］	van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population⁃based multinational assessment of psoriasis and psoriatic arthritis survey［J］. J Eur Acad Dermatol Venereol, 2015,29（10）:2002⁃2010. doi: 10.1111/ jdv.13150.
［8］	Wang Y, Coyne K, Sofen H, et al. Qualitative analysis and reproducibility assessment of the scalp itch numeric rating scale among patients with moderate to severe plaque psoriasis of the scalp［J］. J Dermatolog Treat, 2019,30（8）:775⁃783. doi: 10. 1080/09546634.2019.1577546.
［9］	Moore C, Gupta R, Jordt SE, et al. Regulation of pain and itch by TRP channels［J］. Neurosci Bull, 2018,34（1）:120⁃142. doi: 10.1007/s12264⁃017⁃0200⁃8.
［10］	Reich A, Mędrek K, Szepietowski JC. Interplay of itch and psyche in psoriasis: an update［J］. Acta Derm Venereol, 2016,96（217）:55⁃57. doi: 10.2340/00015555⁃2374.
［11］	Reich A, Welz⁃Kubiak K, Szepietowski JC. Pruritus differences between psoriasis and lichen planus［J］. Acta Derm Venereol, 2011,91（5）:605⁃606. doi: 10.2340/00015555⁃1129.
［12］	Nigam R, El⁃Nour H, Amatya B, et al. GABA and GABA（A） receptor expression on immune cells in psoriasis: a pathophysiological role［J］. Arch Dermatol Res, 2010,302（7）:507⁃515. doi: 10.1007/s00403⁃010⁃1052⁃5.
［13］	Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch⁃associated cutaneous factors［J］. Br J Dermatol, 2003,149（4）:718⁃730. doi: 10.1046/j.1365⁃2133.2003.05586.x.
［14］	Arck P, Paus R. From the brain⁃skin connection: the neuroendocrine⁃immune misalliance of stress and itch［J］. Neuroimmunomodulation, 2006,13（5⁃6）:347⁃356. doi: 10.1159/000104863.
［15］	Gupta K, Harvima IT. Mast cell⁃neural interactions contribute to pain and itch［J］. Immunol Rev, 2018,282（1）:168⁃187. doi: 10.1111/imr.12622.
［16］	Zhou Y, Follansbee T, Wu X, et al. TRPV1 mediates inflammation and hyperplasia in imiquimod （IMQ）⁃induced psoriasiform dermatitis （PsD） in mice［J］. J Dermatol Sci, 2018,92（3）:264⁃271. doi: 10.1016/j.jdermsci.2018.11.009.
［17］	Chang SE, Han SS, Jung HJ, et al. Neuropeptides and their receptors in psoriatic skin in relation to pruritus［J］. Br J Dermatol, 2007,156（6）:1272⁃1277. doi: 10.1111/j.1365⁃2133. 2007.07935.x.
［18］	Nattkemper LA, Tey HL, Valdes⁃Rodriguez R, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch［J］. J Invest Dermatol, 2018,138（6）:1311⁃1317. doi: 10.1016/j.jid.2017.12. 029.
［19］	Sakai K, Sanders KM, Youssef MR, et al. Role of neurturin in spontaneous itch and increased nonpeptidergic intraepidermal fiber density in a mouse model of psoriasis［J］. Pain, 2017,158（11）:2196⁃2202. doi: 10.1097/j.pain.0000000000001025.
［20］	Kupczyk P, Reich A, Gajda M, et al. UCHL1/PGP 9.5 dynamic in neuro⁃immune⁃cutaneous milieu: focusing on axonal nerve terminals and epidermal keratinocytes in psoriatic itch［J］. Biomed Res Int, 2018,2018:7489316. doi: 10.1155/2018/748 9316.
［21］	Kim TW, Shim WH, Kim JM, et al. Clinical characteristics of pruritus in patients with scalp psoriasis and their relation with intraepidermal nerve fiber density［J］. Ann Dermatol, 2014,26（6）:727⁃732. doi: 10.5021/ad.2014.26.6.727.
［22］	Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a Phase 2b clinical trial in patients with psoriasis［J］. Acta Derm Venereol, 2015,95（5）:542⁃548. doi: 10.2340/00015555⁃2047.
［23］	Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch［J］. Br J Dermatol, 2011,165（2）:277⁃284. doi: 10.1111/j.1365⁃2133. 2011.10347.x.
［24］	Kou K, Nakamura F, Aihara M, et al. Decreased expression of semaphorin⁃3A, a neurite⁃collapsing factor, is associated with itch in psoriatic skin［J］. Acta Derm Venereol, 2012,92（5）:521⁃528. doi: 10.2340/00015555⁃1350.
［25］	Hunter HJ, Hinz R, Gerhard A, et al. Brain inflammation and psoriasis: a ［11 C］⁃（R）⁃PK11195 positron emission tomography study［J］. Br J Dermatol, 2016,175（5）:1082⁃1084. doi: 10.1111/bjd.13788.
［26］	Takahashi N, Tominaga M, Kosaka R, et al. Involvement of µ⁃opioid receptors and κ⁃opioid receptors in itch⁃related scratching behaviour of imiquimod⁃induced psoriasis⁃like dermatitis in mice［J］. Acta Derm Venereol, 2017,97（8）:928⁃933. doi: 10.2340/00015555⁃2704.
［27］	Kupczyk P, Reich A, Hołysz M, et al. Opioid receptors in psoriatic skin: relationship with itch［J］. Acta Derm Venereol, 2017,97（5）:564⁃570. doi: 10.2340/00015555⁃2595.
［28］	Aizawa N, Ishiuji Y, Tominaga M, et al. Relationship between the degrees of itch and serum lipocalin⁃2 levels in patients with psoriasis［J］. J Immunol Res, 2019,2019:8171373. doi: 10.1155/2019/8171373.
［29］	Wiśnicka B, Szepietowski J C, Reich A, et al. Histamine, substance P and calcitonin gene⁃related peptide plasma concentration and pruritus in patients suffering from psoriasis［J］. Dermatol Psychosom, 2004,5（2）:73⁃78. doi: 10.1159/0000 79211.
［30］	Prignano F, Ricceri F, Pescitelli L, et al. Itch in psoriasis: epidemiology, clinical aspects and treatment options［J］. Clin Cosmet Investig Dermatol, 2009,2:9⁃13. doi: 10.2147/ccid.s4465.
［31］	Elewski B, Alexis AF, Lebwohl M, et al. Itch: an under⁃recognized problem in psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（8）:1465⁃1476. doi: 10.1111/jdv.15450.
［32］	Théréné C, Brenaut E, Barnetche T, et al. Efficacy of systemic treatments of psoriasis on pruritus: a systemic literature review and meta⁃analysis［J］. J Invest Dermatol, 2018,138（1）:38⁃45. doi: 10.1016/j.jid.2017.05.039.
［33］	Stull C, Grossman S, Yosipovitch G. Current and emerging therapies for itch management in psoriasis［J］. Am J Clin Dermatol, 2016,17（6）:617⁃624. doi: 10.1007/s40257⁃016⁃0213⁃5.
［34］	Bulur I, Erdogan HK, Aksu AE, et al. The efficacy and safety of phototherapy in geriatric patients: a retrospective study［J］. An Bras Dermatol, 2018,93（1）:33⁃38. doi: 10.1590/abd1806⁃4841. 20185468.
［35］	Väkevä L, Niemelä S, Lauha M, et al. Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: results from an observational multicenter study［J］. Photodermatol Photoimmunol Photomed, 2019,35（5）:332⁃338. doi: 10.1111/phpp.12479.
［36］	Rodríguez⁃Granados MT, Estany⁃Gestal A, Pousa⁃Martínez M, et al. Is it useful to calculate minimal erythema dose before narrowband UV⁃B phototherapy?［J］. Actas Dermosifiliogr, 2017,108（9）:852⁃858. doi: 10.1016/j.ad.2017.05.009.
［37］	Smith CH, Jabbar⁃Lopez ZK, Yiu ZZ, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2017［J］. Br J Dermatol, 2017,177（3）:628⁃636. doi: 10.1111/bjd.15665.
［38］	Zachariae C, Gordon K, Kimball AB, et al. Efficacy and safety of ixekizumab over 4 years of open⁃label treatment in a phase 2 study in chronic plaque psoriasis［J］. J Am Acad Dermatol, 2018,79（2）:294⁃301.e6. doi: 10.1016/j.jaad.2018.03.047.
［39］	Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis［J］. Arch Dermatol, 2005,141（1）:31⁃38. doi: 10.1001/archderm.141.1.31.
［40］	Puig L, Augustin M, Blauvelt A, et al. Effect of secukinumab on quality of life and psoriasis⁃related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52⁃week study［J］. J Am Acad Dermatol, 2018,78（4）:741⁃748. doi: 10.1016/j.jaad.2017.10.025.
［41］	Ständer S, Luger T, Cappelleri JC, et al. Validation of the itch severity item as a measurement tool for pruritus in patients with psoriasis: results from a phase 3 tofacitinib program［J］. Acta Derm Venereol, 2018,98（3）:340⁃345. doi: 10.2340/00015555⁃2856.
［42］	Dickison P, Swain G, Peek JJ, et al. Itching for answers: Prevalence and severity of pruritus in psoriasis［J］. Australas J Dermatol, 2018,59（3）:206⁃209. doi: 10.1111/ajd.12747.
［43］	D′Erme AM, Zanieri F, Campolmi E, et al. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate⁃severe psoriasis and psychiatric comorbidity: a retrospective study［J］. J Eur Acad Dermatol Venereol, 2014,28（2）:246⁃249. doi: 10.1111/j.1468⁃3083.2012.04690.x.

[1]	Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848.
[2]	Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844.
[3]	Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802.
[4]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.
[5]	Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705.
[6]	Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650.
[7]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[8]	China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401.
[9]	Lian Panpan, Liu Jun, Su Zhonglan, Wang Hongwei. Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes [J]. Chinese Journal of Dermatology, 2023, 56(4): 365-368.
[10]	Jin Liping, Zhu Wu, Lu Yan, Liu Panpan, Tan Minjia, Wang Ying, Yang Jing, Xu Licong, Hu Kun, Kuang Yehong. Dietary intervention for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(4): 357-360.
[11]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[12]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[13]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[14]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[15]	Chen Lianghong, Sun Yan, Wang Jingyu, Wu Yan. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210875-e20210875.

Pruritus in psoriasis: clinical characteristics, pathogenesis and treatment

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［43］

Related Articles 15

Metrics

Comments

Recommended 10